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Abstract
Background: Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a
frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and
higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function
after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride
concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft
function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function
after deceased donor kidney transplantation is unknown.
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Methods: BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized
controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced,
low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased
donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney
transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either
intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required;
whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined
as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite
of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality,
graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled,
randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry.
Discussion: If using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves
other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced
low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of
transplant settings worldwide.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12617000358347. Registered on 8 March 2017.
ClinicalTrials.gov: NCT03829488. Registered on 4 February 2019.
Keywords: Balanced crystalloid, Delayed graft function, End-stage kidney disease, Intravenous fluids, Kidney
transplantation, Peri-operative care, Plasma-Lyte 148, Pragmatic trial, Registry trial, Normal saline
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Introduction
Background and rationale {6a}
End-stage kidney disease (ESKD) is a significant public
health problem worldwide and its treatment imposes a
high healthcare burden and cost. Kidney transplantation
is considered the best treatment for ESKD, offering
improved survival and quality of life at significantly
lower cost than dialysis [1, 2]. However, there is a
shortage of available donor organs, and many kidney
transplants fail prematurely due in part to injury
sustained around the time of transplantation.
Delayed graft function (DGF), the requirement for
dialysis due to poor kidney function in the early post-
operative period, is an increasingly frequent complica-
tion of deceased donor kidney transplantation, with a
current estimated incidence of 30% or greater [3, 4]. In
addition to a longer length of hospital stay, higher costs,
and an increased risk of acute rejection in the immediate
post-transplant period [5–7], DGF is associated with
reduced graft function and inferior graft and patient sur-
vival in the long term [6, 8].
DGF reflects acute kidney injury caused by ischemia-
reperfusion injury during transplantation, and is driven
by donor, recipient, and transplant factors [9, 10]. It re-
sults from hypoxia and inflammation induced by
hypotension, vasospasm, cytokine release and activation
of the innate immune system [10], and it can occur prior
to and during organ procurement, during storage and
transport, and in the recipient following reperfusion of
the graft. Interventions that have reduced the incidence
of DGF include treatment of the deceased organ donor
with hypothermia or dopamine prior to retrieval [11, 12]
and machine perfusion of the donor kidney during
transport and storage [13]. However, logistics and high
costs remain significant barriers to the widespread appli-
cation of these approaches, and there are currently no
established interventions in the recipient that can reduce
the incidence of DGF.
Intravenous fluid therapy is a critical, albeit
inexpensive, aspect of peri-operative care for the trans-
plant recipient that is required to maintain intravascular
volume and optimize graft perfusion and function. Iso-
tonic sodium chloride (“normal” or 0.9% saline) is the
standard crystalloid solution utilized at most centers
[14]. However, 0.9% saline may be harmful due to its
high chloride concentration relative to plasma (Table 1),
which causes hyperchloremic metabolic acidosis. This in
turn may lead to acute kidney injury and DGF as a result
of renal vasoconstriction and kidney tissue edema [15–
17]. Furthermore, metabolic acidosis frequently leads to
hyperkalemia, increasing the risk of arrhythmias and car-
diac instability, further exacerbating kidney injury [18].
Therefore, utilizing a balanced low-chloride crystalloid
solution, such as Plasma-Lyte 148 (Plasmalyte) as an al-
ternative to 0.9% saline may result in improved out-
comes after kidney transplantation.
Studies in surgical and intensive care patients
administered relatively low volumes of fluid have shown
modest reductions in measures of acute kidney injury
and dialysis, with balanced low-chloride crystalloids
compared with 0.9% saline [19–23]. In kidney trans-
plantation, studies have shown reduced acidosis with
low-chloride solutions compared with 0.9% saline, how-
ever, they have been insufficiently powered to detect im-
portant differences between the groups for DGF and
other transplant outcomes [24]. Moreover, these results
are not necessarily generalizable to the typical deceased
donor kidney transplant setting, as two thirds of studies
involved recipients of living donor kidneys (at very low
risk of DGF), and trial fluids were only given intra-
operatively in relatively low volumes. However, in a re-
cent blinded randomized trial conducted in deceased
donor kidney transplant recipients who received fluid
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volumes more typical of clinical practice (median 6–7 L
from surgery until post-operative day two), the incidence
of hyperkalemia was significantly lower with Plasmalyte
compared with 0.9% saline, and a post-hoc analysis
showed improvements in several measures of graft func-
tion [25]. Definitive trials in high-risk populations, in-
cluding deceased donor kidney transplant recipients, are
therefore still required.
The Better Evidence for Selecting Transplant Fluids
(BEST-Fluids) trial is a randomized controlled trial
designed to test the hypothesis that intravenous (IV)
fluid therapy with a balanced low-chloride crystalloid so-
lution, Plasmalyte, compared with 0.9% saline, will re-
duce the incidence and severity of acute kidney injury
and delayed graft function in deceased donor kidney
transplant recipients.
Objectives {7}
The primary objective of the BEST-Fluids trial is to
compare the effect of peri-operative IV fluid therapy
using Plasmalyte with that of fluid therapy using 0.9%
saline on the incidence of delayed graft function (DGF)
in deceased donor kidney transplant recipients.
The secondary objectives are to determine whether
peri-operative IV therapy using Plasmalyte, compared
with 0.9% saline, (1) improves the recovery of graft func-
tion in the first week after transplantation; (2) reduces
the number of dialysis treatments required and the dur-
ation of dialysis dependence after transplantation; (3) re-
duces the incidence and severity of hyperkalemia; (4)
improves graft survival and death-censored graft survival
at 12 months; (5) improves graft function up to 12
months post-transplant; (6) improves health-related
quality of life; (7) reduces hospital length of stay and
health-related costs; and (8) is cost-effective.
Trial design {8}
BEST-Fluids is an investigator-initiated, pragmatic,
registry-based, prospective, multi-center, parallel-group,
double-blind, randomized, active-controlled, superiority
trial. An outline of the trial is shown in Fig. 1. An assess-
ment of the pragmatic design aspects of the trial using
the Pragmatic-Explanatory Continuum Indicator Sum-
mary 2 (PRECIS-2) tool [26] is shown in Fig. 2 and de-
scribed in more detail in Additional file 1.
The Australasian Kidney Trials Network (AKTN, The
University of Queensland) is the sponsor and
coordinating center for the trial. The Australia and New
Zealand Dialysis and Transplant (ANZDATA) Registry
is being used for participant enrolment, randomization,
and follow-up data collection.
The first trial participant was enrolled on 30 January
2018 and recruitment is expected to be completed in
December 2020, with 12-month follow up of all partici-
pants scheduled to be completed by December 2021.
Methods: participants, intervention, and
outcomes
Study setting {9}
A total of 800 participants undergoing deceased donor
kidney transplantation will be recruited at hospitals in
Australia and New Zealand. Additional file 2 contains a
list of the study sites.
Eligibility criteria {10}
Inclusion criteria
The inclusion criteria are:
1. Adult or child with end-stage kidney disease from
any cause and on maintenance dialysis or who has
chronic kidney disease with an estimated
Table 1 Physicochemical characteristics of selected electrolyte solutions and human plasma
0.9% Saline Ringers Lactate Plasmalyte Human plasma
Sodium (mmol/L) 154 130 140 136–145
Potassium (mmol/L) 0 4 5 3.5–5.0
Magnesium (mmol/L) 0 0 1.5 0.8–1.0
Calcium (mmol/L) 0 2.7 0 2.2–2.6
Chloride (mmol/L) 154 109 98 98–106
Acetate (mmol/L) 0 0 27 0
Gluconate (mmol/L) 0 0 23 0
Lactate (mmol/L) 0 28 0 0
pH 6.8 6.5 7.4 7.35–7.45
Osmolarity (mOsm/L) 308 273 295 280–296
Calculated osmolality in vivoa (mOsm/kg) 287 254 271
Isotonic with plasma Yes Nob Yes
aSodium and chloride are only partially osmotically active with an osmotic coefficient of 0.926
bRingers Lactate is hypotonic compared with plasma
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glomerular filtration rate (eFGR) of < 15 mL/min/
1.73m2 (as determined by the Chronic Kidney Dis-
ease - Epidemiology Collaboration (CKD-EPI) equa-
tion for adults [27] or the bedside Schwartz
equation for children) [28];
2. Planned deceased donor kidney transplant from an
organ donor in whom brain death (DBD) or
circulatory death (DCD) is expected to occur within
the next 24 h;
3. Written informed consent or consent given by their
parent or guardian (if the participant is age < 18
years) or other authorized person.
Exclusion criteria
The exclusion criteria are:
1. Planned live donor kidney transplant (except where
this is cancelled in favor of transplantation from a
deceased donor);
2. Planned multi-organ transplant (dual or en-bloc kid-
ney transplants are not excluded);
3. A child with weight < 20 kg or a child who the
treating physician believes should not be included
in a blinded study of fluids due to their small body
size;
Fig. 1 Outline of the BEST-Fluids trial. ESKD, end-stage kidney disease; CKD, chronic kidney disease
Collins et al. Trials          (2020) 21:428 Page 5 of 19
4. Known hypersensitivity to the trial fluid
preparations or packaging.
The risk of DGF after live donor kidney
transplantation [10] is very low (< 10%), thus patients
undergoing this procedure are excluded. Multi-organ
(heart-kidney, liver-kidney or pancreas-kidney) trans-
plants have different surgical and management ap-
proaches that would confound the trial. Small children,
particularly those under 20 kg in weight, are more sus-
ceptible to electrolyte imbalances due to the volumes of
IV fluid therapy required post-transplantation, and they
have been excluded for safety reasons. Patients with
known hypersensitivity to the solutions or trial fluid
packaging are also excluded for safety reasons.
Who will take informed consent? {26a}
Patients who are admitted for a deceased donor kidney
transplant at participating hospitals are invited to
participate in the trial. Clinical staff (physicians or
resident medical staff) determine participant eligibility,
discuss the trial, and seek informed consent during
routine transplant pre-operative assessments. All clinical
staff involved in obtaining consent and enrolling
participants have received specific training in the trial
and the requirements of Good Clinical Practice (GCP);
they do not necessarily need to be investigators or re-
search staff.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Additional written consent is sought from Australian
participants to utilize routinely collected individual
health data on outpatient healthcare use from the
Medicare Benefits Schedule (MBS) and prescription
medicines from the Pharmaceutical Benefits Scheme
(PBS), which will be used in the economic evaluation.
This additional consent is not required in New Zealand
as specific consent to utilize health information linked to
the National Health Index database is incorporated into
the main consent form.
Participants are also asked for their consent to have
their radiology images, data, and reports from
ultrasound scans or nuclear medicine scans, performed
post-transplant, collected for analysis in a separate im-
aging sub-study. No additional biological samples out-
side those collected as part of routine clinical care are
being collected from participants.
Fig. 2 Pragmatic aspects of trial design. The Pragmatic-Explanatory Continuum Indicator Summary 2 (PRECIS-2) wheel for the BEST-Fluids trial.
Scores in each domain range from 1 (very explanatory) to 5 (very pragmatic) as described in Loudon et al. [26]. This PRECIS-2 wheel was
generated using the tool available at www.precis-2.org
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Interventions
Explanation for the choice of comparators {6b}
There is physiological and clinical evidence to support
the hypothesis that using a balanced low-chloride solu-
tion, such as Plasmalyte, as IV therapy in deceased
donor kidney transplantation may reduce the potential
for adverse effects, including acute kidney injury and
DGF, which could occur due to the high-chloride con-
tent of 0.9% saline. Available low-chloride solutions that
could be utilized as IV crystalloid therapy in transplant-
ation include Plasmalyte, Hartmanns or Ringers Lactate,
and Elomel Isoton (Fresenius Kabi). Hartmanns/Ringers
Lactate has been used intra-operatively in trials involving
transplant recipients, but has the disadvantage of being a
hypotonic solution (osmolality 254 mOsm/kg), increas-
ing the risk of post-operative hyponatremia, especially
when used in significant volumes as occurs in trans-
plantation. Elomel Isoton, which has been used in a trial
of deceased donor transplant recipients, is similar to
Plasmalyte, except that acetate is the sole buffer (Plas-
malyte contains both acetate and gluconate buffers);
however, it is not currently licensed in Australia and
New Zealand. Plasmalyte is licensed in Australia, New
Zealand, and many other countries, is readily available
and already in use at many centers, and was recently
evaluated for safety and potential efficacy in a small trial
involving deceased donor kidney transplant recipients
[29]. Thus, Plasmalyte was selected as the experimental
low-chloride crystalloid fluid therapy for this trial.
Numerous observational studies in the surgical setting
have associated the use of 0.9% saline with an increased
risk of acute kidney injury [19, 22, 23, 30–33]. However,
as with all observational studies, these findings may be
affected by selection bias and residual confounding,
making causal inferences problematic. Two prospective
pilot studies (the SPLIT-ICU and SALT trials) in the in-
tensive care setting [34, 35] evaluating the effects of
buffered crystalloid solutions versus 0.9% saline reported
no differences between patient groups in the rate of
major adverse kidney events. More recently, in two large
multiple crossover cluster trials involving > 20,000 non-
critically ill and critically ill adult patients, the use of
Hartmann’s solution or Plasmalyte resulted in a lower
rate of major adverse kidney events when compared to
0.9% saline [20, 21]. Importantly, these studies did not
discriminate between patients undergoing kidney trans-
plant and other patients and did not involve individual
blinding of the treatment assignments.
In the context of major surgery, the effects of
restricting peri-operative use of IV chloride on kidney
injury were examined in the LICRA and SOLAR trials
[36, 37]. In both studies, there was no clinically mean-
ingful difference in the risk of a composite of in-hospital
mortality and major post-operative complications,
including acute kidney injury. Patients undergoing kid-
ney transplantation were excluded. Accordingly, there
are no current guidelines on which crystalloid solution
should be used in deceased donor kidney
transplantation.
Currently, IV therapy with 0.9% saline is the standard
of care at the majority of transplant centers in Australia
and New Zealand. In a 2016 survey of 22 renal
transplant centers conducted by several of the authors
(MC, MF, DR, CH, and SC), 64% reported using 0.9%
saline intra-operatively and 87% reported using it post-
operatively (unpublished observations), which is similar
to published studies from other countries [14]. Hence,
0.9% saline was chosen as the standard of care to use as
the control therapy in this trial.
Intervention description {11a}
Participants will be randomized to one of two blinded
fluid-therapy groups:
1. Plasmalyte: low-chloride, balanced crystalloid solu-
tion, Plasma-Lyte 148 (approx. pH 7.4) IV Infusion
(Baxter Healthcare, Toongabbie, NSW, Australia)
or
2. 0.9% Saline: isotonic Sodium Chloride (0.9%) IV
Infusion BP (Baxter Healthcare, Toongabbie, NSW,
Australia).
The allocated trial fluid is administered blinded as the
routine IV fluid therapy for all maintenance,
replacement, and resuscitation purposes. The fluid is
administered from randomization onwards pre-
operatively, intra-operatively, and post-operatively, until
either IV fluid therapy is no longer required or until 48
h post-transplant, whichever is earliest. The rate and vol-
ume of fluid administration are not mandated by the
study protocol and are prescribed by treating physicians
according to usual center practice.
Participants are each allocated an individual box
containing 12 × 1000 mL bags of blinded trial fluid
labelled with a unique 4-digit study code (treatment
pack number). The treatment pack number is provided
by the randomization system (accessed via ANZDATA),
corresponding with an available box at the study site.
The box of allocated fluids remains physically with the
participant during their hospital stay, and is transported
with them to the operating theatre and other hospital lo-
cations as required. A further two boxes of 12 × 1000mL
fluid bags can be allocated by the randomization system
prior to 48 h post-transplant, allowing up to 36 L of trial
fluid to be used per participant if required. Each
uniquely labelled box can be allocated to one participant
only.
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Criteria for discontinuing or modifying allocated
intervention {11b}
Blinded trial fluids may be temporarily or permanently
discontinued by the treating clinician or investigator at
any time if (1) the IV fluids are no longer indicated or
required, (2) there is an indication for a specific open-
label fluid that cannot be co-administered with study
fluids, (3) a serious adverse event occurs that may be re-
lated to fluid therapy, (4) continuation is deemed not to
be in the participant’s best interests, or (5) if requested
by the treating physician or participant.
Once the 48-h post-transplant timepoint is reached,
participants who continue to require IV fluids may be
continued on trial fluids beyond 48 h, until the stock of
fluid bags within a previously allocated box is exhausted.
Alternatively, participants may be converted to open-
label fluids prescribed by the treating physician at their
discretion.
Strategies to improve adherence to interventions {11c}
A face-to-face initiation meeting was held prior to the
commencement of the trial at each site. Site investiga-
tors and research staff engaged with their multidisciplin-
ary teams and provided training and tailored local
resources to support adherence to the intervention, in-
cluding checklists, trial alert notices in the medical re-
cords, handover documents affixed to the patient’s
hospital bed, and trial fluid accountability logs. Presenta-
tions on the trial were typically given by site investiga-
tors at meetings of clinicians involved in transplant peri-
operative care, including transplant and anesthesia de-
partments, to maximize awareness and engagement.
Monitoring visits by the staff from the trial coordinating
center are conducted periodically to evaluate risk mitiga-
tion strategies and confirm adequate study fluid supplies,
training, and resources to meet site needs.
Relevant concomitant care permitted or prohibited
during the trial {11d}
The use of other non-trial fluids, such as blood products,
are permitted as per routine clinical care and treating
physician discretion. The use of non-trial open-label
crystalloids is permitted in specific circumstances (e.g.
hypotonic solutions for hypernatremia, or for adminis-
tration of IV medications), but is otherwise discouraged
in the absence of a compelling clinical indication.
All participants receive usual transplant management
as per the local standard of care. This includes peri-
operative anesthesia and invasive monitoring, circulatory
support, surgical care, immunosuppression, routine
prophylactic measures, the management of fluid over-
load, hyperkalemia and other electrolyte disturbances,
and other complications. Hyperkalemia is treated as per
standard practice and local protocols. Dialysis is
performed for standard clinical indications, as deter-
mined by treating clinicians. Further details of protocol
recommendations for concurrent participant manage-
ment, including the use of open-label crystalloids and
other fluid therapy, are outlined in Additional file 3.
Provisions for post-trial care {30}
Following completion of the trial intervention at 48 h
post-transplant, participants are followed up until 12
months post-transplant. All post-transplant care is pro-
vided by the hospital where the transplant takes place or
other local hospital, as per routine practice. The Sponsor
has indemnity insurance to cover those who suffer from
potential harm due to participation in the trial. New
Zealand participants are eligible to apply for compensa-
tion from the New Zealand Accident Compensation
Corporation (ACC) for treatment-related injuries that
occur due to participation in the trial.
Outcomes {12}
Primary outcome measure
The primary outcome is the proportion of participants
with DGF, defined as those receiving treatment with any
form of dialysis in the first 7 days after transplant.
Secondary outcome measures
The secondary outcome measures include the following:
1. Early Kidney Transplant Function, measured using
a ranked composite of (a) the duration of delayed
graft function in days for the participants requiring
dialysis, and (b) the rate of transplant graft function
recovery measured by creatinine reduction ratio on
day 2 (CRR2) [38] for the participants who do not
receive dialysis. CRR2 (%) = ([creatinineday 1-
creatinineday 2]*100)/creatinineday1 (see
Additional file 4 for further details).
2. The number of dialysis sessions (in the first 28
days), and the total duration of dialysis in days
(from transplant to the final dialysis treatment).
3. Creatinine reduction ratio on day 2 post-transplant,
and the proportion of participants with a decrease
in serum creatinine of ≥ 10% on 3 days consecu-
tively in the first 7 days post-transplant.
4. Serum creatinine trends over 52 weeks.
5. Incidence of serum potassium ≥ 5.5 mmol/L and
peak potassium level in the first 48 h post-
transplant.
6. Treatment for hyperkalemia with dialysis, IV
calcium, insulin, β-agonists, sodium bicarbonate, or
ion exchange resins in the first 48 h post-transplant.
7. Incidence of significant fluid overload, defined as >
5% weight gain (baseline to day 2).
8. Aggregate urine output until day 2 post-transplant.
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9. Requirement for inotropic support, both intra-
operatively and post-operatively, to day 2.
10. Number of acute rejection episodes in the first 52
weeks.
11. Number of renal transplant biopsies performed in
the first 28 days post-transplant.
12. Mortality up to 52 weeks.
13. Graft survival and death-censored graft survival at
52 weeks.
14. Graft function (eGFR derived from serum
creatinine using the CKD-EPI equation [27] (adults)
or the bedside Schwartz equation [28] (children) at
4, 12, 26, and 52 weeks.
15. Health-related quality of life, as measured by the
EuroQol five dimensions questionnaire (EQ-5D-5 L)
for adults and by the EuroQol five dimensions
Youth questionnaire (EQ-5D-Y) for children aged <
18 years.
16. Length of hospital stay, healthcare resource use and
cost-effectiveness over 12 months.
Participant timeline {13}
Participants are followed up in the study from
randomization until 52 weeks after transplant surgery.
Figure 3 shows the schedule of enrolment, interventions,
and assessments. Data collection occurs at baseline,
post-operatively (on arrival to the post-anesthetic recov-
ery unit after transplant surgery), on days 1, 2, 7, and 28,
and on weeks 12, 26, and 52 (see Additional file 5 for
further details).
Sample size {14}
The sample size for the BEST-Fluids trial (800 partici-
pants) is based on a comparison between two independ-
ent groups of the proportions of participants
experiencing the primary outcome measure of DGF. The
effect size, or minimum clinically important difference,
was determined by considering that a relative risk (RR)
reduction of approximately 25% (RR of 0.75) for the in-
cidence of the primary outcome would be both clinically
meaningful and within the range of biological plausibility
for the association between DGF and Plasmalyte versus
0.9% saline. The latter is based on trends observed in (1)
the Weinberg trial [29]: RR of dialysis within 48 h post-
transplant of 0.78 (95% confidence interval (CI) 0.47 to
1.28) and (2) a recently published before-and-after non-
randomized interventional study [39]: RR for dialysis
within 48 h of 0.3 (95% CI 0.10 to 0.97; adjusted odds ra-
tio 0.14; 95% CI 0.03 to 0.48), as the most current and
relevant data available.
A sample size of 722 participants (361 per group) will
have 80% power at a 5% two-sided significance level to
show an estimated absolute difference between the
groups of 10% (41% versus 31%), with an estimated
overall incidence of DGF of 36% and RR for Plasmalyte
versus 0.9% saline of 0.76. Allowing for 4.0% non-
adherence (estimated 2% drop-out from the Plasmalyte
group and 2% drop-in) and up to 1% loss to follow up
for the primary outcome measure (e.g. due to death or
withdrawal of consent within 7 days), an adjusted sample
size of 792 participants is required. To allow for fluctua-
tions in these estimates, a total of 800 participants will
be recruited.
While the target recruitment allows for 1% loss to
follow up, it is expected that loss to follow-up in this
study for both the primary outcome (7 days) and second-
ary outcomes (up to 12months) will be close to zero
due to (1) the very close clinical follow up that renal
transplant recipients routinely receive, (2) the short
timeframe for ascertainment of the primary outcome (7
days post-transplant), and (3) the fact that transplant re-
cipients are highly motivated patients who typically
maintain strong engagement with their care providers.
Recruitment {15}
BEST-Fluids is being conducted at 13 adult hospitals
and 3 children’s hospitals that perform kidney
transplants in Australia and New Zealand. Collectively
these hospitals performed more than 500 deceased
donor kidney transplants annually in the year prior to
trial commencement; thus, approximately 50–55% of
eligible patients overall need to be enrolled to meet the
target sample size of 800 over 3 years.
Strategies have been implemented to achieve optimal
participant enrolment: comprehensive site engagement
with members of the multi-disciplinary clinical team
prior to initiation of the trial, a pragmatic trial design
with broad eligibility criteria, recruitment of participants
by clinical staff who usually undertake the pre-operative
assessments prior to transplant at each site, consent
forms written in plain English (with interpreters avail-
able where required), a simple, rapid randomization
process accessed online using ANZDATA, and the align-
ment of trial processes and the study intervention with
usual clinical care. Each site has been provided with
training on and resources for the trial, including short
online randomization training videos to familiarize them
with the ANZDATA Registry web-based platform used
for enrolment. With few exceptions, participants are
already being treated with dialysis and are registered in
the ANZDATA Registry prior to being admitted for
transplant, which greatly simplifies the process of enrol-
ment. On-call 24-h telephone support is provided to
clinical staff who are enrolling participants, with the
ability to access assistance for enrolment and
randomization from an investigator on the coordinating
committee.
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Fig. 3 Participant timeline. Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist. Enrolment, interventions and
assessments. EQ-5D-5L, EuroQol five dimensions, 5 levels questionnaire; EQ-5D-Y, EuroQol five dimensions, Youth questionnaire
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Assignment of interventions: allocation
Sequence generation {16a}
Participants are randomized 1:1 to either Plasmalyte or
0.9% saline, using an adaptive minimization method
[40]. The minimization algorithm is designed to ensure
balance across the two treatment groups for factors
associated with DGF and graft outcomes, including:
1. Transplant center [41];
2. Deceased donor status (donation after brain death,
donation after circulatory death);
3. Machine perfusion (no, yes); and
4. Australian Kidney Donor Risk Index (KDRI) tertile.
The KDRI is a composite measure of donor quality
based on eight donor characteristics known at the
time of transplantation [42, 43].
Concealment mechanism {16b}
The list of unique study codes (treatment pack
numbers) and treatment allocations accessed by the
minimization algorithm, and the algorithm itself, are
stored centrally in an external web-based randomization
system provided by the NHMRC Clinical Trials Centre
at The University of Sydney, and are not accessible to in-
vestigators, study staff, or staff at the ANZDATA
Registry.
Implementation {16c}
The code for generating the treatment pack numbers
and treatment allocations was developed by an un-
blinded statistician who is not a member of the study
team. Participants are enrolled and randomized by site
staff using the ANZDATA Registry web-based platform,
which communicates with the randomization system via
a secure web-based connection built into the registry
system that is not accessible to end users. The
randomization system returns a unique participant study
identification number and treatment pack number to the
ANZDATA Registry, which then displays this informa-
tion to the site staff member and sends an auto-email to
their email address and the AKTN trial coordinating
center.
Assignment of interventions: blinding
Who will be blinded? {17a}
Study participants, treating physicians and other
healthcare providers, outcome assessors, research staff,
study investigators, staff at the AKTN trial coordinating
center, ANZDATA Registry staff, and the primary trial
statistician are blinded. Details of the treatment
allocations and unique treatment pack numbers are
known only to a specified un-blinded statistician, the
Baxter Healthcare manufacturing team, and data staff at
the NHMRC Clinical Trials Centre.
The Plasmalyte and 0.9% saline preparations and
packaging used in this study are manufactured by Baxter
Healthcare Pty Ltd. (Toongabbie, NSW, Australia)
specifically for the trial, and, apart from their labelling,
are identical to those used in standard clinical practice
in Australia and New Zealand. The trial fluid allocation
is masked by using a specifically designed printed trial
label that does not allow the identification of the specific
fluid type (Fig. 4). Prior to shipment of the boxes from
the manufacturer to study sites, each trial fluid box is
labelled externally with the 4-digit treatment pack num-
ber. A set of two pre-printed adhesive labels with the
same code are affixed to the outside of the protective
covers over individual bags in the box, to allow the bags
within the box to be labelled by clinical staff once
opened.
Procedure of unblinding if needed {17b}
Unblinding is not permitted during the trial except in
the event of a serious adverse event. One of the lead
Principal Investigators (MC) is the main contact for sites
to discuss any request for unblinding and will remain
blinded. If unblinding is deemed necessary, the time,
date and reason will be recorded and the un-blinded
statistician will contact the healthcare professional in-
volved at the site. Only those who need to know will be
made aware of the treatment allocation. The participant
will remain in the study and, where possible, continue
their allocated study treatment.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Participants are enrolled, randomized and followed up
using ANZDATA, which is a long-standing, bi-national
clinical quality registry that collects incidence, preva-
lence, and outcome data on dialysis and kidney trans-
plantation in Australia and New Zealand. Trial processes
are embedded within the registry to improve trial effi-
ciency by avoiding data entry duplication, enhancing in-
tegration into routine care, and facilitating long-term
follow up. Clinical and laboratory data are collected by
study staff from the participant’s medical record. Infor-
mation on health-related quality of life is collected by
participant completion of the EQ-5D-5L questionnaire
for adults, and the EQ-5D-Y questionnaire for children.
Plans to promote participant retention and complete
follow up {18b}
It is anticipated that participants will be in hospital for
all visits prior to day 7, with subsequent visits timed to
coincide with routine outpatient clinic appointments
undertaken as part of standard post-transplant care. The
study team collect the data required for each visit from
clinical records of outpatient clinic attendances and
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laboratory tests performed as part of routine care at the
location this is being provided. If a participant transfers
to another center/referring renal unit away from the pri-
mary transplant center for ongoing care, the study visit
data can be collected from day 28 (visit 6) onwards via
telephone or electronic mail from local treating physi-
cians/nursing staff, and via post, email or telephone from
participants for the collection of the EQ-5D quality of
life questionnaires. Participants are not required to at-
tend the study site for any study visits after hospital dis-
charge. If a participant no longer wishes to complete the
quality of life questionnaires, other study data will con-
tinue to be collected from clinical records and the
ANZDATA Registry, unless the participant specifically
withdraws consent for this to occur.
Data management {19}
The ANZDATA Registry web-based system is used for
collection of trial outcomes data. Selected data elements
routinely captured by ANZDATA will be utilized for
trial purposes, including baseline participant characteris-
tics, acute rejection, graft function, graft survival, and
patient survival. Data on donor characteristics will be
collected through linkage with the Australia and New
Zealand Organ Donation Registry (ANZOD), which is
administered and managed by ANZDATA. Data ele-
ments collected specifically for the BEST-Fluids trial are
directly entered into the registry via an additional trial
data collection module. REDCap (Research Electronic
Data Capture), a secure, web-based software platform
designed to support data capture for research studies
[44] is used to collect data on protocol deviations and
serious adverse events (SAEs), as well as sub-study data.
Confidentiality {27}
Any information that may identify a participant will be
excluded from the data presented in the public arena.
All study-related information is stored securely at each
study site, and local databases are secured with
password-protected access systems. All copies of clinical
records, reports, data collection, process, and adminis-
trative forms are identified by a coded identification
number only.
Participant information submitted to the ANZDATA
Registry for this trial includes individual identifiers and
demographic details, and along with routine non-trial
registry data collection, is stored on secure servers at the
South Australian Health and Medical Research Institute
(SAHMRI) in Adelaide, Australia. ANZDATA acts in ac-
cordance with Australian and New Zealand national
Fig. 4 Masking of study fluid. The printed label design on the study fluid bag does not allow identification of the type of study fluid (right hand
image). Two adhesive stickers with the unique study code (treatment pack number) are attached to the exterior protective over-pouch (not
shown), one of which is applied to the bag itself, along with a patient label, when the bag is opened by clinical staff (left hand image)
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privacy principles and has detailed policies and proce-
dures for data management to safeguard privacy and
confidentiality (see https://www.anzdata.org.au/anzdata/
services/data-policies/). Staff at study sites have access to
identified information about their site’s participants held
in ANZDATA for the purpose of data entry and query
resolution during the trial. Staff at the AKTN trial co-
ordinating center only have access to de-identified trial
data.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
the trial/future use {33}
No biological specimens are being collected in this
study.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
The effect of treatment, Plasmalyte versus 0.9% saline,
on the primary outcome of DGF will be analyzed using a
log-binomial regression model, with treatment group,
three minimization variables (donor status (DBD, DCD),
machine perfusion (no, yes), KDRI tertile), and ischemic
time [8–10] as predictor variables (fixed effects) in the
model, and study center as a random effect. Sensitivity
analyses will adjust for potential confounding due to any
baseline characteristics that are substantially unbalanced
between the treatment groups.
The effect of treatment on secondary outcomes will be
analyzed using statistical methods appropriate for the
type of outcome. Secondary outcomes are variously
binary, ordinal, count, and time to event. Binary
secondary outcomes will be analyzed using log-binomial
regression. Ordinal outcomes will be analyzed using the
Wilcoxon rank-sum test and ordinal logistic regression.
Count outcomes will be analyzed using Poisson regres-
sion models. If there is under-dispersion or over-
dispersion, residuals will be examined to determine the
most suitable model (e.g. quasi-Poisson regression, nega-
tive binomial regression). Continuous outcomes will be
compared using linear regression or an appropriate non-
parametric test if assumptions are not met. Mortality
and graft survival will be analyzed using Kaplan-Meier
curves, the log rank test, and Cox regression.
Analyses will be by intention to treat; participants will
be included in the intention-to-treat analysis if they are
randomized and receive a deceased donor kidney trans-
plant within 48 h of randomization. Participants whose
transplant does not proceed will be excluded from ana-
lysis of the primary and secondary outcomes, although
those who receive trial fluids will be included in analysis
of safety outcomes. Adverse events will be tabulated by
treatment group. Depending on the amount and type of
data, differences between treatment groups in adverse
events may be tested by binary logistic or Poisson re-
gression. All analyses will be described in a detailed stat-
istical analysis plan made publicly available before data
analysis commences and treatment allocations are un-
blinded.
Interim analyses {21b}
There are no formal interim analyses planned.
Methods for additional analyses {20b}
A cost-effectiveness analysis of the interventions will be
conducted from a health funder perspective, with the hy-
pothesis that using Plasmalyte rather than 0.9% saline
will be a dominant intervention, i.e. will be both more
effective and less costly. Information on health-related
quality of life derived from the EQ-5D questionnaires
will be used to calculate utilities and quality-adjusted life
years (QALYs). Resource use for the index transplant-
ation will include the costs of fluids, hospitalizations,
dialysis, laboratory tests, hospital clinics, physician visits,
procedures, prescribed treatments, and medications. In
addition, over the 12 months, data on healthcare re-
source use will be obtained for Australian participants
via linkage to the Admitted Patient Data Collection in
each state, and Medicare Australia for outpatient health
service use for Australian patients (medical and pharma-
ceutical - Medicare Benefits Schedule (MBS), and the
Pharmaceutical Benefits Scheme (PBS)). For New Zea-
land participants, data on resource use will be obtained
via linkage using the National Health Index number with
the national data collections (including the National
Minimum Dataset, Mortality Collection, Laboratory
Claims Collection, Pharmaceutical Collection, and others
as appropriate) held by the Ministry of Health. Unit
costs will be obtained from the most recent and relevant
Australian-Refined Diagnosis Related Group costs (AR-
DRG) and MBS and PBS costs.
Incremental cost-effectiveness ratios (ICERs) will be
calculated as costs per life year and QALY gained at 12
months using the mean costs and health outcomes in
the Plasmalyte group compared with the 0.9% saline
group. Results will be plotted on a cost-effectiveness
plane, with bootstrapping used to estimate the distribu-
tions of costs and health outcomes, to estimate confi-
dence intervals for the ICERs, and to generate cost-
effectiveness acceptability curves. Sensitivity analyses will
be explored.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Analyses will be performed on the intention-to-treat
population (as described above). An adherence-adjusted
analysis will be performed on the primary outcome if
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there is more than 4% non-adherence to treatment or
differential adherence across treatments. All analyses, in-
cluding any methods used to handle missing data, will
be described fully in the pre-specified statistical analysis
plan.
Plans to give access to the full protocol, participant-level
data, and statistical code {31c}
The full trial protocol and the statistical code used for
analysis will be made publicly available after publication
of the primary results of the trial. Individual participant
data that underlie the results reported in the primary
publication, after de-identification (text, tables, figures
and appendices), will be available for individual partici-
pant data meta-analysis, beginning 2 years and ending 5
years after the main publication. Proposals may be sub-
mitted up to 5 years after article publication. After 5
years, the data will be available in our University’s data
warehouse but without investigator support other than
deposited metadata. An independent review board will
assess proposals based on the following criteria: sound
science, benefit-risk balancing, and research team
expertise.
Oversight and monitoring
Composition of the coordinating committee and Trial
Steering Committee {5d}
The coordinating committee includes the co-chairs of
the Trial Steering Committee (TSC) and a member of
the AKTN executive committee as a deputy chair. Mem-
bers include a subset of TSC members, AKTN’s project
management staff and the AKTN statistician, with add-
itional expertise co-opted as required (e.g. Registry staff
or health economists). The committee is responsible for
oversight and direction on operational aspects of the
study, and provides regular reports and secretariat sup-
port to the TSC.
The TSC is co-chaired by the lead Principal Investiga-
tors for the study and includes AKTN executive mem-
bers, AKTN project management staff, ANZDATA
Registry staff, nephrologist investigators from adult and
pediatric hospitals, an anesthetist, surgeon, transplant
nurse practitioner, statistician, and two health econo-
mists. The TSC is responsible for obtaining funding (in-
cluding grant writing as required), drafting and
amending the protocol and other key trial documents,
monitoring recruitment, data entry completion and
quality, and drafting and approving the statistical ana-
lysis plan and other trial publications. The TSC receives
reports from the Data Safety Monitoring Board (DSMB)
and is responsible for decisions concerning the continu-
ation, modification or termination of the trial following
recommendations from the DSMB.
Composition of the data monitoring committee, its role,
and reporting structure {21a}
An independent DSMB has been formed and operates in
accordance with a trial-specific DSMB Charter. Mem-
bers have no financial or scientific conflicts of interest
with the BEST-Fluids trial. The DSMB chair is a clin-
ician with extensive clinical trials and DSMB experience.
The DSMB statistician is an experienced clinical trials
statistician with extensive DSMB experience. Additional
members are clinicians with clinical trials and DSMB
experience.
The DSMB remit is to protect the safety of trial
participants and the scientific integrity of the trial by
monitoring the accumulating safety and operational
data, and meets approximately every 6 months during
the trial. There are no formal statistical guidelines for
early stopping. Following each of its meetings to date (as
of March 2020), the DSMB has recommended that the
trial continue without changes to the trial protocol.
Under the DSMB charter, the investigators retain sole
decision-making responsibility for modifications to, or
early stopping of, the trial.
Adverse event reporting and harms {22}
Serious adverse events (SAEs) that are considered
related to study treatment are monitored and reported
up until day 7 post-transplant. Study-specific reportable
adverse events, including hyperkalemia (up to day 7),
dialysis (up to week 12), death, acute rejection episodes,
and graft loss, are also being monitored during the trial.
In addition to including details of SAEs and study-
specific reportable adverse events reported by study
sites, reporting for the DSMB was modified in 2019 after
a request for additional safety data, to include adminis-
trative coding data from hospital discharge summaries
to allow tabulation of discharge diagnoses, complica-
tions, and procedure codes recorded during the index
transplant admission for each participant. These data are
extracted periodically from clinical records by local hos-
pital coding staff at each site and submitted to the
AKTN for inclusion in DSMB safety reports. In the con-
text of this pragmatic trial, this measure was added to
enable capture of any unanticipated adverse events and
thereby ensure sufficient monitoring of trial participant
safety.
Frequency and plans for auditing trial conduct {23}
GCP compliance monitoring is being conducted by the
Sponsor. Risk-based monitoring is in place for the study.
Plans for communicating important protocol
amendments to relevant parties {25}
All protocol amendments will be approved by
responsible independent ethics committees and local site
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governance prior to implementation. Trial registration
information has been updated with the amendment
information. No amendments have been made to the
protocol that have required re-consent from
participants.
Dissemination plan {31a}
Trial findings will be disseminated at national and
international scientific meetings, by publication in a
scientific journal, and through submission of the results
to trial registration databases. Authorship for all trial
publications will be based on criteria formulated by the
International Committee of Medical Journal Editors,
available at www.icmje.org.
Additionally, results will be disseminated to trial
participants, study staff, clinicians, and patient groups
via direct approaches, and a variety of traditional and
electronic media, including newsletters, on social media
and the AKTN website.
Discussion
Interventions that reduce the impact of delayed graft
function (DGF) in kidney transplantation have the
potential to improve transplant outcomes and reduce
costs. This multi-center, prospective, randomized,
double-blind, pragmatic trial has been designed to deter-
mine whether the type of fluid therapy used peri-
operatively in transplantation is important, specifically
whether 0.9% saline given to a recipient exacerbates
ischemia-reperfusion-injury-associated acute kidney in-
jury and DGF, and whether using a balanced low-
chloride alternative could prevent these adverse effects.
Given that IV fluid therapy is both inexpensive and a
critically important aspect of kidney transplant care, evi-
dence for the superiority of Plasmalyte over 0.9% saline
from this trial would provide strong justification for a
change in clinical practice to using balanced crystalloids
as the standard of care. Given the relatively large sample
size and the expected generalizability of results to other
transplant populations, a finding of no significant differ-
ence between the groups for the primary and key sec-
ondary outcomes with clinically important differences
outside the bounds of the confidence intervals for effect
estimates would imply that any benefit with balanced
low-chloride crystalloids over 0.9% saline either does not
exist, or is not clinically important for the majority of
deceased donor kidney transplant recipients. Similarly,
although the results of previous trials would make such
findings unexpected, better outcomes with 0.9% saline
would justify continuing with this type of fluid as the
standard of care. Regardless, BEST-Fluids will provide
important data on the relative safety of these two fluid
types, particularly in relation to any electrolyte
abnormalities, such as hyperkalemia, or other peri-
operative complications.
In keeping with the pragmatic study design, and to
maximize the generalizability of the study findings,
eligibility criteria were designed to enroll a broad range of
deceased donor kidney transplant recipients, with an
estimated incidence of DGF of 30–40%. It is estimated
that > 95% of deceased donor transplant recipients are
eligible for this trial. Trial processes have been designed to
be integrated into routine clinical care at participating
hospitals, with multiple pragmatic aspects enabling
transplant clinicians to easily enroll their patients without
necessarily requiring the presence of research staff, and to
prescribe the trial fluid intervention with maximum
flexibility while maintaining a blinded treatment
allocation. All data collected, apart from the quality of life
questionnaires, are either already routinely collected or
readily available in the clinical record; no additional
laboratory tests or procedures are required for the trial.
By using a registry-based trial design, we sought to
align trial processes with clinical practice using estab-
lished registry data collection practices. Registry trial de-
signs have a number of potential advantages in terms of
increased efficiency, lower costs, alignment with stand-
ard clinical care, and reduction in investigator burden
[45]. Staff at participating hospitals in BEST-Fluids are
familiar with ANZDATA and the requirements of its
data collection; 100% of renal units in Australia and
New Zealand contribute data on patients treated with a
kidney transplant. A purpose-built point-of-care data
entry system for ANZDATA was rolled out to staff in
renal units at around the time that recruitment com-
menced in the BEST-Fluids study; trial processes includ-
ing enrolment, randomization and data collection have
been incorporated into this system with the use of an
additional integrated software module.
There are two other significant advantages of using
the registry-based design. First, because ANZDATA
contains data on all kidney transplant recipients in
Australia and New Zealand, it will be possible to directly
compare BEST-Fluids participants with the population
of transplant recipients who are non-participants (who
either had their transplant at a center not involved in
the trial or who underwent transplantation at a partici-
pating hospital but are not enrolled for other reasons).
This will enable an assessment of external validity and
generalizability of the study findings through a compari-
son of patient characteristics and outcomes between
these two groups. Second, all participants will continue
to have data submitted to ANZDATA by local renal unit
staff as per usual practice for death, graft failure, and
other outcomes after the 12-month trial follow up ends,
which will facilitate long-term follow up of trial partici-
pants at minimal cost.
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An important consideration in the design for this trial
was whether or not to exclude patients found to have
hyperkalemia prior to enrolment. Pre-operative hyperka-
lemia is a not infrequent occurrence in patients with
ESKD who are admitted for surgery, including trans-
plantation. Some previous trials of low-chloride solu-
tions versus 0.9% saline in transplant recipients have
excluded patients with hyperkalemia (pre-operative
serum potassium > 5.5 mmol/L) due to concerns about
the potassium content of low-chloride fluids (Plasmalyte,
Ringers Lactate, and/or Elomel Isoton) [24]. Addition-
ally, the manufacturer of Plasmalyte recommends cau-
tion with its use in patients with hyperkalemia [46].
However, these concerns have not been borne out in
studies to date, which have not demonstrated increased
hyperkalemia in patients receiving balanced low-chloride
solutions. In the Weinberg trial [29], there was signifi-
cantly less hyperkalemia in the Plasmalyte group, despite
this study only excluding patients with untreated pre-
operative potassium > 6.0 mmol/L. It therefore seems
likely that Plasmalyte does not cause clinically significant
hyperkalemia despite its potassium content (5 mmol/L,
similar to plasma). Moreover, the low-chloride concen-
tration may confer a protective effect, even in the setting
of poor graft function and oliguria, due to avoidance of
hyperchloremic acidosis combined with the inclusion of
gluconate and acetate anions as bicarbonate precursors.
Potential trial participants with pre-operative hyperkale-
mia are therefore not excluded from BEST-Fluids, which
is consistent with the pragmatic approach to eligibility
criteria and will ensure maximum applicability of the
trial findings. The protocol recommends that treating
physicians actively manage and treat pre-operative
hyperkalemia > 6.0 mmol/L prior to transplant surgery
(as would be considered usual clinical practice), thereby
minimizing the potential risk. Hyperkalemia will be re-
ported as an important secondary outcome for the trial.
In the protocol for BEST-Fluids originally approved by
ethics committees and in operation at the time enrol-
ment commenced in January 2018 (protocol version 2.0,
13 June 2017), the primary outcome measure was Early
Kidney Transplant Function; a novel outcome measure
incorporating two commonly used measures of DGF: (1)
the duration of DGF in days in participants requiring
dialysis and (2) the rate of transplant graft function re-
covery measured by creatinine reduction ratio on day 2
(CRR2) [38] for participants who do not receive dialysis.
After a review of the rates of recruitment, protocol ad-
herence and DGF in the first 113 trial participants, the
study protocol was amended in 2018 (Protocol version
3.0, 22 October 2018) to change the primary outcome to
a binary outcome measure based simply on the inci-
dence of DGF (defined as dialysis within 7 days of trans-
plant) and increase the sample size from the original
number of 574 to the current sample size of 800 partici-
pants. These changes were made to align the trial pri-
mary outcome with other, similar contemporary trials of
interventions for DGF, and to make it easier for clini-
cians to interpret the trial results, with the ultimate goal
of facilitating a rapid translation of the trial findings into
practice. The original primary outcome has been
retained as a key secondary outcome measure; further
details of this outcome measure and the original sample
size calculation are provided in Additional file 4.
A particular strength of BEST-Fluids is its random-
ized, blinded design, with the use of minimization to
ensure balance between treatment groups for relevant
factors that impact the risk of the primary outcome
of DGF. Blinding is particularly important for avoid-
ance of bias in a trial of this type, where the primary
outcome (DGF, the requirement for dialysis in the
first post-transplant week) involves a clinical decision
made by physicians caring for the patient. Further-
more, there is significant heterogeneity in the inci-
dence of DGF between centers, even after adjustment
for patient-level and center-level characteristics,
suggesting that local transplant practices and clinician
propensity to utilize dialysis during the post-
transplant period vary considerably [41].
There are some limitations that need to be considered.
By design, BEST-Fluids does not mandate any specific
approaches to the volume of IV fluid therapy to use ei-
ther during surgery or in the post-operative period, and
fluid volume may be an important risk factor for the de-
velopment of DGF. In a recent trial of patients undergo-
ing major abdominal surgery, a liberal approach to fluid
therapy was associated with a reduced risk of acute kid-
ney injury compared with a more restrictive approach,
in contrast to previous studies that had suggested that
liberal fluid therapy was associated with inferior out-
comes due to tissue edema, fluid overload, and other
post-operative complications [47]. Data on fluid volume
and weight change are being collected in BEST-Fluids.
Both the duration of cold ischemic time (from retrieval
until implantation commences) and warm ischemic time
(from rewarming to reperfusion of the graft following
completion of vascular anastomoses) are major factors
that affect the risk of DGF [9, 10], which are not incor-
porated into the randomization allocation algorithm as
this information is not available at the time of enrolment
into the study. However, the primary analysis of the ef-
fects of treatment on the primary outcome will be ad-
justed for total ischemic time, in addition to the
minimization variables. Additional pre-specified analyses
of the primary and key secondary outcomes will include
separate adjustment for cold and warm ischemic times,
fluid volume, and change in weight as a measure of fluid
overload.
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In conclusion, BEST-Fluids is an ongoing randomized,
controlled, pragmatic, registry-based trial that will pro-
vide the most definitive comparative effectiveness data
to date on DGF and other important clinical outcomes,
using Plasmalyte versus 0.9% saline in deceased
donor kidney transplantation. If the hypothesis that Plas-
malye is superior to 0.9% saline is proven, this will pro-
vide an important and inexpensive means to improve
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